Beneficial neurological effects observed in a patient with psoriasis treated with etanercept.
A 53-year-old woman with a history of psoriasis presented with severe cutaneous lesions associated with psoriasis. The woman was mentally handicapped; she was able to converse monosyllabically with her mother only and was very limited in social interactions. After preliminary investigations, a biological treatment was proposed. Etanercept was started in October 2006. The patient responded rapidly and, after 3 months, achieved a 75% improvement in the psoriasis area and severity index (PASI 75) score. Most notable, however, was that she began interacting with other people, even if they were not familiar to her. Subsequent cutaneous relapses were treated successfully with etanercept. Very few articles regarding etanercept and neurological or psychiatric problems are present in the literature. According to recent studies, etanercept could improve verbal fluency and cognitive and behavioural functions in Alzheimer's disease, so that we can suggest a potential role and use in neurological disorders.
Bassi
Elisa
E
Department of Dermatology, Siro Delmati Hospital, Strada Provinciale 19, 26866 Sant'Angelo Lodigiano (Lo), Italy. elisa_bassi@yahoo.it
De Filippi
Claudia
C
D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012008:Recurrence; D012720:Severity of Illness Index; D016896:Treatment Outcome
D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept